No Record Found
Sector
PharmaceuticalsOpen
₹4.5Prev. Close
₹4.5Turnover(Lac.)
₹0Day's High
₹4.5Day's Low
₹4.552 Week's High
₹052 Week's Low
₹0Book Value
₹-0.55Face Value
₹5Mkt Cap (₹ Cr.)
2.71P/E
0EPS
0Divi. Yield
04 Aug 2025
12:00 AM
Board Meeting
Agenda : Audited Result
3 Sep 2024
12:00 AM
AGM
Announcement Date: 03 Sep, 2024
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -3.35 | -3.21 | -3 | -3 |
Net Worth | -0.34 | -0.2 | 0 | 0 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0.06 | 0.03 |
yoy growth (%) | 0 | -100 | 91.58 | -57.78 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | 0 | 0 | 0 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Profit before tax | -0.07 | -0.01 | -0.05 | 0 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.04 | 0.14 | -0.06 | 0.02 |
Other operating items |
| Y/e 31 Mar | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | -100 | 91.58 | -57.78 |
Op profit growth | 108.25 | -15.78 | -1,227.9 | -81.97 |
EBIT growth | 315.55 | -66.02 | -1,227.9 | -81.97 |
Net profit growth | 314.16 | -65.9 | -1,514.38 | -82.15 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,580.4 | 76.13 | 3,79,190.9 | 753.53 | 1.01 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,026.05 | 68.48 | 1,59,972.69 | 557 | 0.5 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,541.4 | 24.1 | 1,24,507.21 | 1,303.13 | 1.04 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,609.9 | 61.46 | 1,22,169.93 | 551 | 0.17 | 2,567 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,578.6 | 58.82 | 1,06,433.9 | 412.76 | 0 | 2,541.36 | 354.69 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Amit Mukeshbhai Shah
Independent Director
Bhavesh Vora
Independent Director
Nilesh Harkesh Yadav
Executive Director
Jaishree Babulal Jain
Independent Director
Dhruval Patel
Executive Director
Surbhit Shah
Independent Director
Chetanbhai Patel
Independent Director
Ilaben Pathak
328 Paradise Complex,
Sayajigunj,
Gujarat - 390005
Tel: 91-265-2362966
Website: http://www.rekvinalaboratories.com
Email: rekvina@gmail.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 91-22-23016761/8261
Website: -
Email: -
Summary
Rekvina Labs Ltd was incorporated on 1st November 1988. The Company is registered in England and Wales as a Public Limited Company. The company is mainly engaged in manufacturing and marketing of phar...
Read More
Reports by Rekvina Labs Ltd
What is the Rekvina Labs Ltd share price today?
What is the Market Cap of Rekvina Labs Ltd?
What is the PE and PB ratio of Rekvina Labs Ltd?
What is the 52 Week High and Low of Rekvina Labs Ltd?
What is the CAGR of Rekvina Labs Ltd?
What is the shareholding pattern of Rekvina Labs Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.